Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Abstract On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2021-08-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202114781 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849332010957406208 |
|---|---|
| author | Giovanna Lalli Jonathan M Schott John Hardy Bart De Strooper |
| author_facet | Giovanna Lalli Jonathan M Schott John Hardy Bart De Strooper |
| author_sort | Giovanna Lalli |
| collection | DOAJ |
| description | Abstract On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain. |
| format | Article |
| id | doaj-art-b58865ed2caa4598874cf2c4fbbe5fbf |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2021-08-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-b58865ed2caa4598874cf2c4fbbe5fbf2025-08-20T03:46:21ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842021-08-011381310.15252/emmm.202114781Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?Giovanna Lalli0Jonathan M Schott1John Hardy2Bart De Strooper3UK Dementia Research Institute at UCLDementia Research Centre, UCL Queen Square Institute of NeurologyUK Dementia Research Institute at UCLUK Dementia Research Institute at UCLAbstract On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.https://doi.org/10.15252/emmm.202114781 |
| spellingShingle | Giovanna Lalli Jonathan M Schott John Hardy Bart De Strooper Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? EMBO Molecular Medicine |
| title | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_full | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_fullStr | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_full_unstemmed | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_short | Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? |
| title_sort | aducanumab a new phase in therapeutic development for alzheimer s disease |
| url | https://doi.org/10.15252/emmm.202114781 |
| work_keys_str_mv | AT giovannalalli aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease AT jonathanmschott aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease AT johnhardy aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease AT bartdestrooper aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease |